TargetBeta
HRH3
histamine receptor H3 · also GPCR97 · Histamine receptors
2 programs in company-led studies act on HRH3, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pitolisantrule | Harmony Biosciences | phase 3 | 82 running | – | ChEMBL |
| samelisantrule | Suven Life Sciences | phase 3 | 31 running | – | ChEMBL |
Conditions their studies are in
- Cataplexy, 1 program
- Cognitive Dysfunction, 1 program
- Diabetes Mellitus, Type 1, 1 program
- Disorders of Excessive Somnolence, 1 program
- Idiopathic Hypersomnia, 1 program
- Myotonic Dystrophy, 1 program
- Prader-Willi Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027pitolisant · Harmony Biosciences · phase 3 · NCT06366464
- Nov 19, 2027samelisant · Suven Life Sciences · phase 3 · NCT07540364
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.